Introduction
According to Global Tuberculosis Report 2016 published by WHO, approximately 10.4 million people have contracted tuberculosis and 1.4 million of them have died as a result [1] . Today, treatment of tuberculosis is long and burdensome, requiring at least 6 months of multidrug chemotherapy [2] . The situation is further complicated by the emergence of multidrug-resistant (MDR) M. tuberculosis and extensively resistant (XDR) M. tuberculosis, and by the infection's fatal synergy with HIV/AIDS [2] . Thus, development of new antitubercular drugs is essential for effective treatment and overall cure of the disease.
We initiated a program to screen potential antitubercular compounds of natural origin that have a new structure and mechanism capable of inhibiting the drug-resistant strains of M. tuberculosis. After extensive screening of 800 compounds of plant origin, we identified plumbagin (a naphthoquinone derivative) as a promising candidate, which was purified from Plumbago auriculata. Next, we had screened a library of compounds that are similar in structure to plumbagin and finally found an active compound, DFC ([5-(3-dimethylaminopropyloxy)-7,12-dioxo-7,12-dihydrodinaphtho [1,2-b;2',3'-d] furan-6-carboxylic acid methyl ester]) [3] . To extend the research on DFC as a new class of antitubercular agent, we designed a combinatorial library based on the dinaphthofurandione structures of DFC. A series of DFC analogs were synthesized and tested for in vitro antitubercular activity and cytotoxicity. Among those analogs, methyl 5-[2-(dimethylamino)ethoxy]-7,12-dioxo-7,12-dihydrodinaphtho [1,2-b:2',3'-d]furan-6-carboxylate (DFC-2) showed superior minimum inhibitory concentration (MIC) against drugsusceptible and -resistant M. tuberculosis [3] . The MIC of DFC-2 against the reference strain M. tuberculosis H37Rv in culture broth was 0.39 μg/ml, and it progressively killed M. tuberculosis inside macrophages at 1× MIC [3] . The 50 % cell cytotoxicity (CC 5 0
) value of DFC-2 against L929 cells was 15.21 μg/ml, which gives this compound a selectivity index of 39 [3] . However, there has been no study that investigates the molecular mechanism of its action in M. tuberculosis. In this study, we have analyzed transcriptional profiles of M. tuberculosis in response to DFC-2 and evaluated its effects on mycolic acid biosynthesis.
Materials and Methods

Synthesis of DFC-2
DFC-2 was synthesized through a simple 3-step procedure 66 mmol) was added dropwise over a period of 10 min at 0°C. Then, the reaction mixture was stirred at RT for 16 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was poured into ice-cold water (800 ml) and stirred for 10 min. The off-white solid formed was filtered, washed with water (300 ml), and dried under vacuum to give 1 (24. 
Determination of Antimycobacterial Susceptibility In Vitro
Microdilution technique. A microdilution technique (MDT) using the colorimetric indicator resazurin was used to assess antitubercular activities previously [4] [5] [6] . We used the resazurin assay to determine the antitubercular activities of the compounds against several strains of M. tuberculosis. Middlebrook 7H9 broth (Difco) including 10% albumin-dextrose-catalase (ADC; BD) and 0.2% glycerol was used in the resazurin assay. In the test, 5 μl of serial 2-fold drug dilutions were added into a 200 μl inoculum (3 × 10 5 CFU/ml) at 12 concentrations, of 12.5 to 0.006 μg/ml, in a 96-well plate. After 7 days of incubation, 20 μl of 0.02% resazurin solution was added to each well, and color changes were assessed after a 48-h incubation at 37°C. A color change from blue to pink shows reduction of resazurin and thus shows bacterial growth. We defined the MIC
for each respective strain as the lowest concentration of a compound that had no color change [5] .
Tube dilution technique. A tube dilution technique (TDT) was previously used to evaluate antibacterial activities of various agents [7, 8] . We applied and standardized the TDT to assess the antitubercular activities of compounds against strains of M. tuberculosis. We determined the MIC Cell viability assay. Total ATP, an energy-dependent parameter, was used for rapid viability assessment after exposure of M. tuberculosis to antibiotics [9] [10] [11] . ATP analysis was assessed as previously described [12, 13] . Briefly, M. tuberculosis H37Rv was exposed to the test compounds from day 0 to day 5 at 37°C, and included with an equal volume of BacTiter-Glo Microbial Cell Viability Assay Kit reagent (Promega) and incubated in the dark for 10 min at 37°C. Luminescence was recorded on a multilabel plate reader (PerkinElmer).
RNA Isolation, RT-PCR, and Microarray
The drug concentrations and time points used were selected after considering previously published studies [14, 15] . After drug treatment, RNA samples from three biological replications were extracted with an RNAprotect bacteria reagent kit (Qiagen) as described by the manufacturer's protocol. RNA samples were reverse transcribed to cDNA with a cDNA synthesis kit (Bio-Rad) as described by the manufacturer's protocol. Primer pairs were designed for PCR confirmation of genes as described in Table 1 . Copies of 16S rRNA were used to normalize the transcript levels of their respective genes [14, 16, 17] . Microarray assay was performed using 3 × 20K microarray chips (http://Mycroarray.com) from a commercial microarray service (Ebiogen, Inc., Korea).
Quantification of Mycolic Acids
To obtain cell wall mycolic acids from M. tuberculosis, previously reported protocols [16, 17] were slightly modified. Cell numbers were adjusted to OD of DFC-2 and INH, respectively. After 5 days of incubation (37°C, 120 rpm), the cells were collected by centrifugation, followed by washing with PBS. The pellets were transferred to 2 ml of 25% methanolic potassium hydroxide (KOH dissolved in methanol and water at 1:1) and mixed thoroughly for 30 sec. Then, all tubes were heated for 1 h at 90°C in an oven and then cooled to room temperature. To precipitate the mycolic acids, 2 ml of chloroform was added, followed by 1.5 ml of 6 N HCl, and then mixed thoroughly for 30 sec. The chloroform layer including the dissolved mycolic acids were then transferred by Pasteur pipette to new glass tubes and oven-heated at 80°C until dried. The resulting precipitate was dissolved in chloroform/methanol (2:1 (v/v)) and transferred into the autosampler for LC-MS/MS. For standardization and optimization of the MS/MS condition, mycolic acid from M. tuberculosis (Sigma Aldrich, Cat No. M4537) was used. Quantification of mycolic acids was evaluated by LC-MS/MS as previously described [15] .
Electron Microscopy
Transmission electron microscopy (TEM). For TEM observations, the mycobacterial cells were fixed in 4% paraformaldehdyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer for overnight. After washing in 0.1 M phosphate buffer, the specimens were postfixed with 1% osmium tetroxide in the same buffer for 1 h. Then, the specimens were dehydrated with a graded series of ethyl alcohol and pure acetone. Specimens were embedded in Epon 812 and then polymerization was performed at 60 o C for 3 days. Ultrathin sections (60-70 nm) were obtained by ultramicrotome (Leica Ultracut UCT, Germany). Ultrathin sections collected on grids (200 mesh) were examined under a transmission electron microscope (ZEISS LIBRA 120).
Scanning electron microscopy (SEM). For SEM observations, the mycobacterial cells were fixed in 4% paraformaldehdyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer for overnight. After washing in 0.1 M phosphate buffer, the specimens were postfixed with 1% osmium tetroxide in the same buffer for 1 h. The specimens were then dehydrated in ascending concentration of ethyl alcohol from 50% to 100% (12 h at each concentration). The specimens were then transferred to hexametyldisilazane and allowed to air dry. All samples were coated with gold using a sputter coater and examined on a LEO-1530 device (Carl Zeiss).
Results and Discussion
Confirmation of Antituberculosis Activity of DFC-2 In Vitro
To confirm the previous study that showed antitubercular activity of DFC-2 [3] , we conducted a MDT, a colorimetric microtiter plate-based drug susceptibility assay [18] . The antitubercular activity of DFC-2 was compared with that of five first-line drugs: INH, RIF, STR, PZA, and EMB. Apparently, the MIC data were reproducible, with only minor variations (Fig. 2) . The MIC
of DFC-2 ranged from 0.19 to 0.39 μg/ml against all tested M. tuberculosis strains. The antitubercular activity of DFC-2 was less effective than that of INH and RIF against drug-sensitive strains, but was far more effective against drug-resistant strains, especially against MDR and XDR. 
Exploring DFC-2-Induced Alterations in Gene Expression in M. tuberculosis H37Rv
Microarray analysis, a powerful tool for studying the molecular basis of genetic interactions, makes it possible to examine the expression of thousands of genes simultaneously [19] . Transcriptional profiling of M. tuberculosis H37Rv was performed using 3,975 whole-genome microarrays in order to measure the effects of DFC-2 relative to a sample of , 24 h) genes were found to have altered expression levels in the DFC-2-treated group. In order to better understand the transcriptional response of M. tuberculosis to DFC-2, we adopted more specific functional classifications as previously described [20] . Hypergeometric distribution [21] [22] [23] was used to determine whether the enrichment of genes within a particular functional category in response to DFC-2 treatment was significant. Under >2 and 5 FC and p < 0.05 conditions, the most affected category was "lipid biosynthesis," commonly seen at 6 and 24 h at 10× MIC Table 2) . Moreover, genes involved in synthesis of fatty and mycolic acids were significantly downregulated (p < 0.001) in response to 10× MIC T D T DFC-2 under 2 and 5 FC cutoff (Table 3) . A full list of microarray data is available as supplementary data.
To confirm the microarray results, we explored the gene transcript levels of 26 genes related to mycolic acid synthesis [24] among three groups of samples: control, 1×, and 10× MIC , respectively (Figs. 3A-3E ). These results are quite a contrast to those of the heat shock protein gene (Fig. 3F) , which is known to be upregulated under stress conditions such as exposure to antibiotics [25] . Among downregulated genes, mycolic acid condensation was the most overrepresented (Fig. 3G) .
LC-MS/MS Analysis of Total Mycolate in DFC-2-Treated M. tuberculosis H37Rv
Our gene transcription results suggested that DFC-2's primary effect is to disrupt mycolic acid synthesis. Therefore, we tested whether DFC-2 affects mycolic acid synthesis in M. tuberculosis. In order to evaluate the inhibition of mycolic acid synthesis in response to DFC-2, we measured mycolic acid levels in M. tuberculosis over a period of 5 days. Interestingly, we found that DFC-2 triggered a reduction in mycolic acid production, showing a similar pattern to that of mycolic acid synthesis inhibitor INH (Fig. 4) [26] . The results of this experiment correspond well with those of a previous study, which reported that ursolic acid reduces mycolic acid levels [15] . The decrease in mycolic acid levels at a low, nontoxic concentration (0.2×, 1× MIC viability strongly suggests that DFC-2 is highly effective in reducing mycolic acid levels in M. tuberculosis [15] .
Observation under Electron Microscopes
The inhibitory properties of DFC-2 on the synthesis of INH and DFC-2-treated cells on day 3 showed the fully lysed cell envelope with the extrusion of intracellular contents (Figs. 5E and 5F ). This effect of INH and DFC-2 on the cellular morphogenesis of M. tuberculosis is consistent with the results presented in a previous study [27] . This result strongly supports the hypothesis of a direct effect of DFC-2 on mycolic acid biosynthesis similar to that of INH.
Comparison of Gene Expression Profiles between INH, ETH, and DFC-2
Mycolic acids are long-chain branched fatty acids that represent the viability, drug resistance, and cell wall integrity of the mycobacteria [28] , whose biosynthesis involves five distinct stages: (i) the synthesis of α-branch fatty acid by FAS-I, (ii) the synthesis of meromycolic acids by FAS-II, (iii) the introduction of functional groups to the meromycolate chain, (iv) the condensation of the α-branch and the meromycolate to produce mycolic acids, and (v) the transfer of mycolic acids to arabinogalactan [29] . In CFU are shown. Experiments were carried out in triplicate and repeated at least three times, and the data are given as the mean values and SEM. *Statistical significance vs. drug-free control using unpaired Student's t-test (*p < 0.05, **p < 0.01). TDT (tube dilution technique) was used to determine the minimum inhibitory concentration (MIC) of DFC-2 (1× MIC, 3.7 µg/ml) and INH (1× MIC, 0.37 µg/ml) in this test. order to evaluate if the mycolic acid synthesis inhibition and cell envelope disruption effects of DFC-2 were coupled with the decrease in transcription of the mycolic acid synthesis-related genes or primary target for DFC-2 in mycolic acid biosynthesis, we went on to perform RT-PCR analysis of kas/FAS-II operon genes (fabD-acpM-kasA-kasBaccD6) that are considered a hallmark of mycolic acid synthesis [24, [30] [31] [32] , in response of M. tuberculosis to treatment with the DFC-2 and mycolic acid biosynthesis inhibitors (INH, ETH) whose target is InhA [33] . Results showed an increase in the expression of the kas/FAS-II operon genes in response to INH or ETH treatment for 2 h, followed by a slow decrease in their expression following 6 and 24 h treatment. Meanwhile, DFC-2 treatment showed a dramatic reduction for 2 h, and the degree of decline slowed down at 24 h (Fig. 6) . The response to INH was similar to that of a previous study where it showed an increase in the expression of the kas/FAS-II operon genes and the effect of DFC-2 was similar to that of another mycolic acid inhibitor, triclosan [32] , which indicates that both INH and DFC-2 potentially inhibit mycolic acid biosynthesis, but their primary targets are different. In summary, our results indicate that DFC-2 inhibits the growth of M. tuberculosis, which may be the result of its effects on mycolic acid biosynthesis. However, the mechanism by which DFC-2 inhibits mycolic acid biosynthesis has yet to be understood. Thus, further studies will be required to investigate the mechanism of action of DFC-2 against M. tuberculosis at the molecular level. The ratio between the number of cDNA copies detected in each sample relative to the drug-free control at 1× MIC (A, C, E) and 5× MIC (B, D, F) is represented. INH, isoniazid; ETH, ethionamide.
